PL2834233T3 - Nowy agonista adrenoreceptora alfa2 - Google Patents

Nowy agonista adrenoreceptora alfa2

Info

Publication number
PL2834233T3
PL2834233T3 PL13719297T PL13719297T PL2834233T3 PL 2834233 T3 PL2834233 T3 PL 2834233T3 PL 13719297 T PL13719297 T PL 13719297T PL 13719297 T PL13719297 T PL 13719297T PL 2834233 T3 PL2834233 T3 PL 2834233T3
Authority
PL
Poland
Prior art keywords
new
adrenoceptor agonists
alpha2 adrenoceptor
alpha2
agonists
Prior art date
Application number
PL13719297T
Other languages
English (en)
Inventor
Tuula Koskelainen
Tero Linnanen
Anna MINKKILÄ
Mikko MÄKELÄ
Antti POHJAKALLIO
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of PL2834233T3 publication Critical patent/PL2834233T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13719297T 2012-04-02 2013-03-28 Nowy agonista adrenoreceptora alfa2 PL2834233T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619109P 2012-04-02 2012-04-02
PCT/FI2013/000013 WO2013150173A1 (en) 2012-04-02 2013-03-28 New alpha2 adrenoceptor agonists
EP13719297.7A EP2834233B1 (en) 2012-04-02 2013-03-28 New alpha2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
PL2834233T3 true PL2834233T3 (pl) 2018-09-28

Family

ID=48224812

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13719297T PL2834233T3 (pl) 2012-04-02 2013-03-28 Nowy agonista adrenoreceptora alfa2

Country Status (25)

Country Link
US (1) US9249127B2 (pl)
EP (1) EP2834233B1 (pl)
JP (1) JP6427096B2 (pl)
KR (1) KR102104228B1 (pl)
CN (1) CN104220437B (pl)
AR (1) AR090557A1 (pl)
AU (1) AU2013244859B2 (pl)
BR (1) BR112014023957B1 (pl)
CA (1) CA2868611C (pl)
DK (1) DK2834233T3 (pl)
ES (1) ES2674945T3 (pl)
FR (1) FR22C1005I2 (pl)
HR (1) HRP20181203T1 (pl)
HU (2) HUE039290T2 (pl)
IL (1) IL234663B (pl)
LT (2) LT2834233T (pl)
MX (1) MX358429B (pl)
NL (1) NL301160I2 (pl)
NO (1) NO2022002I1 (pl)
PL (1) PL2834233T3 (pl)
PT (1) PT2834233T (pl)
RU (1) RU2642065C2 (pl)
SI (1) SI2834233T1 (pl)
TW (1) TWI620746B (pl)
WO (1) WO2013150173A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015152196A1 (ja) * 2014-03-31 2017-04-13 東レ株式会社 イミダゾリン誘導体及びその医薬用途
EP3256466B9 (en) * 2015-02-11 2022-07-27 Sunovion Pharmaceuticals Inc. 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
CN105646306B (zh) * 2015-12-11 2020-06-30 广东莱佛士制药技术有限公司 一种4-甲硫基苯乙酸的制备方法
WO2019106238A1 (en) * 2017-12-01 2019-06-06 Orion Corporation Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof
CN110272407B (zh) * 2019-07-22 2021-02-05 河北省农林科学院经济作物研究所 一种用于降血压的天然异色满酮类化合物
CA3212160A1 (en) * 2021-03-19 2022-09-22 Johanna KUJALA Tasipimidine formulations and use thereof
MX2024009068A (es) 2022-01-24 2024-07-30 Orion Corp Nuevas formas de sales de sulfato de un agonista adrenoceptor alfa-2a estructurado con isocroman-imidazol.
CN118715218A (zh) 2022-02-04 2024-09-27 奥赖恩公司 异色满-咪唑结构的α-2A肾上腺素受体激动剂的新盐型
JP2025531623A (ja) 2022-09-28 2025-09-22 オリオン コーポレーション タシピミジンおよびcyp2d6阻害薬の併用療法
CN117343036A (zh) * 2023-03-20 2024-01-05 江苏联环药业股份有限公司 异苯并二氢吡喃类化合物及其药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1247008B (de) * 1965-10-05 1967-08-10 Huels Chemische Werke Ag Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
EP0166937B1 (en) * 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
BR9813381A (pt) * 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
AU2007209382A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of CNS disorders
BRPI0706759A2 (pt) 2006-01-27 2011-04-05 Hofmann La Roche Ag F Uso de derivados de 4-imidazol para distúrbios do cns
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Also Published As

Publication number Publication date
JP2015512438A (ja) 2015-04-27
KR102104228B1 (ko) 2020-04-27
FR22C1005I1 (fr) 2022-03-11
LTPA2022001I1 (pl) 2022-02-25
RU2642065C2 (ru) 2018-01-24
EP2834233A1 (en) 2015-02-11
CA2868611A1 (en) 2013-10-10
KR20140138826A (ko) 2014-12-04
US9249127B2 (en) 2016-02-02
HK1205115A1 (en) 2015-12-11
AR090557A1 (es) 2014-11-19
CN104220437A (zh) 2014-12-17
TWI620746B (zh) 2018-04-11
JP6427096B2 (ja) 2018-11-21
HRP20181203T1 (hr) 2018-10-05
PT2834233T (pt) 2018-07-17
BR112014023957B1 (pt) 2022-03-29
BR112014023957A2 (pt) 2017-06-20
AU2013244859B2 (en) 2017-06-22
NL301160I2 (nl) 2022-04-06
CN104220437B (zh) 2017-11-10
NO2022002I1 (no) 2022-01-27
HUS2200005I1 (hu) 2016-04-28
EP2834233B1 (en) 2018-04-25
TW201400478A (zh) 2014-01-01
CA2868611C (en) 2020-07-21
DK2834233T3 (en) 2018-06-18
ES2674945T3 (es) 2018-07-05
LTC2834233I2 (pl) 2024-07-10
US20150065550A1 (en) 2015-03-05
SI2834233T1 (en) 2018-08-31
MX2014011851A (es) 2014-11-21
WO2013150173A1 (en) 2013-10-10
IL234663A0 (en) 2014-11-30
RU2014144284A (ru) 2016-05-27
FR22C1005I2 (fr) 2024-10-25
LT2834233T (lt) 2018-06-11
AU2013244859A1 (en) 2014-10-02
HUE039290T2 (hu) 2018-12-28
IL234663B (en) 2019-07-31
BR112014023957A8 (pt) 2021-06-15
MX358429B (es) 2018-08-20

Similar Documents

Publication Publication Date Title
HUS2200005I1 (hu) Új alfa2 adrenoceptor-agonisták
GB2515970B (en) Cable holder
IL235512A0 (en) New methods
SG11201404663RA (en) Electroformed sheath
IL239074A0 (en) Pyridine-amides are useful as cb2 antagonists
IL237988A (en) Pyridine-2-affluent cb2 receptor agonists
EP2808919A4 (en) BATTERY SUPPORT
GB2509331B (en) Umbilical
AU345447S (en) Dress-shaped organizer
EP2881497A4 (en) ELECTRO-SILVER PLATING FLUID
GB201506603D0 (en) Photobioreactor
IL239239A0 (en) bra
ZA201504014B (en) Emersed shellfish storage
GB2504569B (en) Needle port
PL2868777T3 (pl) Urządzenie do powlekania elektrolitycznego
GB2509214B (en) Brassiere
GB201116152D0 (en) Cannabinoid-2-receptor agonists
GB2499824B (en) Umbilical
GB201209007D0 (en) Log holder
PL2836101T3 (pl) Stojak na choinkę
GB201116151D0 (en) Cannabinoid-2-receptor agonists
GB201216674D0 (en) Holder
AU341052S (en) Needle holder
GB201216854D0 (en) Agonist
ZA201407546B (en) Ferrule